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MR SPECTROSCOPY/NMR SPECTROSCOPY-BASED METABOLOMICS IN BRAIN TUMOR
Metabolomics is the "systematic study of the unique chemical fingerprints that specific cellular processes leave behind", the study of their smallmolecule metabolite profiles. 1 Recently, metabolomics in cancer research is gaining considerable importance. The application of Nuclear Magnetic Resonance (NMR)-based and Magnetic Resonance Spectroscopy (MRS)-based metabolomics as applied to brain cancer is an evolving area of clinical use and investigation. In brain tumors, diagnosing tumor type and grade non-invasively has been a clinical challenge. 1 H MRS/NMR-based metabolomics has been explored to identify elevated metabolites in malignant tissue specifically in contrast with normal brain. Interestingly, most of the 1 H MRS in vivo studies to date have been done on the brain. This is primarily owing to the reduced effects of motion and lipid contamination in the brain. The global metabolic profile of live cells or cell extracts from established glioma models has been determined using standard NMR methods, and validated using tumor biopsies obtained from animal models or patients that have been imaged using high-resolution magic angle spinning spectroscopy. 2, 3 Such approaches complement data to the in vivo findings.
Detected Metabolites Using 1 H MR Spectroscopy
metabolites, see De Graaf. 4 In the field of neurooncology, the most prevalent metabolites in the 1 H MR spectrum are N-acetylasparate (NAA), total choline-containing metabolites (Cho), lactate (Lac), mobile lipids, creatine (Cre), glutamate (Glu), glutamine (Gln), Gln and Glu, glycine, glutathione, and 2-hydroxyglutarate (2-HG). The largest signal in normal healthy brain tissue is NAA and the NAA level typically decreases in gliomas. 5 The Cho signal is a composite of free choline, phosphocholine and glycerophosphocholine, which are the precursors and breakdown products of the main membrane phospholipid phosphatidylcholine. The intensity of this peak is associated with cell proliferation and cell signaling, and is typically increased in cancer. 6 Lactate is the end product of aerobic glycolysis and is enhanced in cancer as part of the Warburg effect. 7 Lipids (long chain fatty acids), especially lipid droplets known as mobile lipids or triglycerides, are rarely observed in the normal brain, but are often increased in glial tumors and are associated with cell death and increased necrosis. 8 The Cre signal is a composite of Cre and phosphocreatine, which are involved in energy metabolism via the creatine kinase reaction. Cre levels vary within normal brain regions and in some cases with tumorigenesis. 9 The amino acid Glu is the most abundant amino acid in the brain and an essential neurotransmitter. In gliomas, glutaminolysis is often required for tumor growth as an anaplerotic source of carbon complementary to glucose metabolism. 2 Finally, with the recent discovery of the isocitrate dehydrogenase (IDH) mutation, the most common mutation in oligodendroglioma and astrocytoma tumors, 10 increased levels of 2-HG, which is produced from a-ketoglutarate (a-KG) by mutant IDH, serve as a clear metabolic indicator for the presence of the mutation within a tumor and can also be detected by 1 H MRS when the mutation is present.
From a technical perspective, it is important to note that the length of the echo time (TE) used in 1 H MRS sequences defines which metabolites can be detected. Using a short TE (<50 ms), most metabolites can be observed, but overlappings between resonances often hampers proper quantification; on the other hand, when using a long TE (>120 ms), only a few metabolites remain visible, but their respective resonances can be readily identified and quantified. 9 Detected Metabolites Using 13 
C MR Spectroscopy
Early 13 C MRS/NMR investigations were used to monitor glucose metabolism and Lac turnover during steady-state hyperglycemia with stable isotopically labeled, [1-13 C] glucose in C6 glioma-bearing rats. 11 Labeling of glucosederived [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] Lac, [4-13 C] Glu, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] Gln, and [1-13 C] glycogen could all be detected. More important, increased labeled Lac with reduced labeling in Glu and Gln were observed when comparing tumor with normal contralateral brain, consistent with the Warburg effect and a reduction in flux into the tricarboxylic acid (TCA) cycle. 13 C MRS studies investigating glioblastoma (GBM) cells and a combination of 13 C-labeled glucose and 13 C-labeled Gln have also shed light on the possible role of Gln in high-grade brain tumors. Conversion of Gln to Lac via glutaminolysis was found to be sufficient to produce NADPH required for fatty acid synthesis. More recently, studies of primary human GBM models in mice infused with 13 C-labeled glucose further demonstrated not only increased glycolysis, but also active glucose metabolism via the TCA cycle to Glu and Gln, confirming that flux via pyruvate dehydrogenase was not suppressed in GBM. However, this study showed limited glutaminolysis. 12 Using 13 C MRS to probe the fate of 13 C-labeled acetate in orthotopic brain tumors, a recent investigation demonstrated that acetate is oxidized via the TCA cycle, together with glucose, to generate labeled Gln and Glu. This identifies an additional metabolite that could help to meet the high biosynthetic and bioenergetic demands of GBM tumor growth. 13 Future studies using additional 13 Clabeled substrates could be envisaged to shed further light on the metabolism of GBM and, as models are being developed, on the metabolism of lower grade brain tumors.
Clinical 1 H MR Spectroscopy
Numerous studies have highlighted the potential benefits of using 1 H MRS to estimate metabolite levels in brain tumors in the clinic. 14 When combined with similar spatial localization techniques that are used in generating anatomic MR images, this strategy can be used to produce maps of the variations in levels of choline containing compounds, Cre, NAA, Lac, and mobile lipids. With increased magnetic field strengths, improvements in scanner hardware and developments in software capabilities, the acquisition time for volumetric data is on the order of 5 to 10 minutes and the spatial resolution of the voxels obtained is typically 0.5 to 1 cm 3 . 15 More recent advances in pulse sequence development and spectral editing schemes have facilitated the detection of metabolites with shorter T 2 relaxation times and lower signal-to-noise ratios such as Glu, Gln, Gln and Glu , and 2-HG, expanding the investigation of potential metabolic processes for both characterizing the spatial extent of gliomas and assessing therapeutic response.
For Tumor Characterization
The first studies to identify metabolic differences between gliomas and normal brain tissue date back to the mid-1990s and used a long TE (144 ms) 1 H MRS acquisition. 16, 17 Since then, numerous studies have shown that elevated levels of Cho and reduced levels of NAA together can distinguish regions of tumor from normal brain, 18, 19 define the spatial extent of abnormal metabolism owing to tumor beyond the contrast-enhancing lesion 20, 21 guide the selection of the biopsy site to the most aggressive part of the tumor 22, 23 and differentiate among tumor grades and types. The Cho-NAA index (CNI) is a metric that has been developed in the clinical setting to describe such changes and has been found to be more robust than ratios and absolute quantification. 24 These in vivo results have been confirmed by correlating with both ex vivo histologic characteristics from image-guided tissue samples and, more recently, 1 H high-resolution magic angle spinning spectroscopy of tumor biopsies to show that regions with increased Cho and reduced NAA relative to normal brain that have a high probability of corresponding to tumor. 22 However, despite the benefits of 1 H MRS imaging in improving sensitivity to metabolically active tumor and differentiating gliomas from metastatic disease, 25 other disease processes such as inflammation can also cause a reduction in neuronal function while increasing cellularity, so alone MRS is not specific enough to differentiate tumor from inflammation. 26 
For Predicting Outcome or Response to Therapy
In high-grade gliomas, higher Cho-to-Cre, higher Cho-to-NAA, higher Lac plus mobile lipids, and lower Cr-to-NAA abnormalities have been found to be associated with poor survival. 27 In lowgrade gliomas, fewer data sets are available on the prognostic value of MRS in the clinic. In one study, increased Cre was found to be a significant predictor for tumor progression and for malignant tumor transformation in grade II gliomas. Gliomas with decreased Cre seemed to have longer progression-free times and later malignant transformation. 28 The information provided by MRS data is complementary to anatomic images and may often be more valuable than the contrast-enhancing lesion in assessing therapeutic response. The spatial extent of the metabolic lesion can also be used to plan focal therapy, such as external beam radiation therapy (RT) and gamma knife radiosurgery, 29 and to assess the response to therapy. 19 Alexander and colleagues 30 showed that the mean tumor Cho/NAA ratio and normalized Cho decreased from baseline to after completion of external beam RT. In this study, patients who exhibited more than a 40% decrease in normalized Cho between midradiotherapy and postradiotherapy studies were associated with shorter survival times and faster disease progression. The Lac/NAA ratio at the fourth week of RT and the change in normalized Cho/Cre between baseline and week 4 of RT were also predictive of the outcome, suggesting the possible benefit of adaptive, response-based radiation treatment.
Although a breadth of MR imaging methods can provide extensive anatomic and functional information about brain tumors, the current use of colocalized 1 H MRS/NMR metabolomics approaches provides valuable information that can help clinicians to determine tumor margins, distinguish between progression and pseudoprogression, characterize tumor grade and IDH status, and predict response to therapy. Additionally, preclinical studies of brain tumor models continue to shed light on the complexities of glioma metabolism, leading to an improved understanding of cellular events that could be targetable for new therapeutic approaches. Furthermore, methods currently optimized in the preclinical setting and most notably the use of hyperpolarized agents, are poised to enter the clinic and will enhance the steady-state metabolic data with dynamic flux information that could further improve the detection of tumors and the early monitoring of therapeutic response. Collectively, the breadth of existing and emerging MRS methodologies available for the metabolic imaging of brain tumors could improve current paradigms significantly on diagnosis, treatment, and response assessment, advancing personalized patient care and quality of life.
GAS CHROMATOGRAPHY/MASS SPECTROMETRY-BASED METABOLOMICS OF BRAIN CANCER
Besides NMR-based metabolomics, metabolomics based on gas chromatography/mass spectrometry are increasingly applied in brain cancer research but at this point are mostly restricted to ex vivo samples. However, mass spectrometry imaging is emerging as a powerful tool for directly determining the distribution of proteins, peptides, lipids, neurotransmitters, metabolites, and drugs in situ 31 and has enormous potential as a clinical tool for interrogating metabolism in brain cancer.
Gas Chromatography/Mass Spectrometry-Based Metabolomic Analysis of Cerebrospinal Fluid from Glioma Patients
Nakamizo and colleagues 32 analyzed cerebrospinal fluid from patients with glioma using gas chromatography/mass spectrometry to correlate metabolomic profiles based on World Health Organization tumor grades, tumor location, contrast in MR images, and IDH mutations. Samples were separated into 3 groups: grade I and II glioma, grade III glioma, and glioblastoma (GBM). Grades I and II and grade III samples did not differ in their metabolomic content. However, in GBM samples, citric and isocitric acid were increased compared with the other 2 groups, and lactic acid was higher relative to grades I and II samples. Succinic, fumaric, and malic acid were decreased in GBM samples relative to grades I and II and grade III gliomas. For samples that originated from tumors proximal to the ventricles, high-grade tumors possessed elevated levels of citric and isocitric acid, and low-grade tumors had elevated levels of lactic acid, compared with samples originating in tumors distal to the ventricles. In high-grade tumors that displayed gadolinium enhancement in MR images, citric and isocitric acid levels were higher than those tumors that did not display this enhancement. Levels of citric, isocitric, and lactic acid were higher in samples with mutated IDH than those with wild-type IDH, whereas the combined signal from pyruvate and oxaloacetic acid was decreased in the mutated IDH samples. The correlation between overall survival and concentrations of these metabolites was also investigated. It was found that in malignant glioma (grades III and IV), elevated levels of lactic acid were correlated to lower overall survival. Although not significant, there was a trend between elevated levels of citric and lactic acid and lower overall survival in all gliomas.
Metabolomic Patterns in Glioblastoma and Changes During Radiotherapy
Wibom and colleagues 33 examined the metabolic profile of GBM patients before and after radiotherapy. Extracellular fluid was extracted from the tumor and brain adjacent to tumor (BAT) via microdialysis before and during treatment, similar to the procedure performed by Tabatabaei and colleagues 34 and was analyzed with gas chromatography time-of-flight mass spectrometry. Reference samples were also collected subcutaneously from the abdomen. Tumor tissue was found to express lower levels of glucose than BAT and the subcutaneous tissue. Several amino acids were found in greater quantities in the tumor relative to the BAT, including the essential amino acids, L-threonine, allothreonine, L-tryptophan, L-arginine, Llysine, and L-valine. Glycine and Glu levels were also increased in the tumor compared with the BAT. After radiotherapy was administered, Glu and Gln levels increased in both tumor and BAT regions. Ethanolamine and glycerol seemed to decrease in the tumor but increase in the BAT in addition to glycerol. Although the metabolic profile varied among the patients, it was suggested that the trends in the tumor metabolome could be monitored individually to help assess the efficacy of radiotherapy.
Metabolomic Screening of Glioma Patients Reveals Diagnostic and Prognostic Information
Moren and colleagues 35 conducted a study that compared the metabolic profiles of tumor samples and serum from different World Health Organization grades of GBM and oligodendroglioma via gas chromatography time-of-flight mass spectrometry. Correlations were determined between metabolite levels and survivability of the 2 diseases. Increased levels of 2-hydroxyglutaric acid, 4-aminobutyric acid (GABA), creatinine, glycerol-2-phosphate, glycerol-3-phosphate, ribitol, and myo-inositol were found in tumor samples, and lysine and 2-oxoisocaproic acid in serum from oligodendroglioma patients, relative to samples from GBM patients. Compared with oligodendroglioma samples, levels of mannitol and phenylalanine in GBM tumor samples and cysteine from serum were increased. Survival groups were split into short survival (4 months) and long survival (3 years), where the survival is measured as the time after diagnosis. In GBM, elevated levels of glycerol-3phoshate, myo-inositol, ribitol, and fructose were associated with long survival. In oligodendroglioma levels of ribitol, myo-inositol and spermidine were higher for long survival patients, whereas short survival patients expressed elevated levels of glycine and aminomalonic acid.
Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma
The first study to delineate the metabolic differences in cerebrospinal fluid samples between malignant and nonmalignant glioma patients was investigated by Locasale and colleagues 36 through the use of a liquid chromatography/tandem mass spectrometry. Several metabolites that were significantly altered between the malignant and nonmalignant samples were identified. A correlation between tumor size and metabolite levels was also determined. Acetylcarnitine, acetoacetate, phenylpropiolic acid, and cholesteryl sulfate were correlated positively with tumor size whereas myo-inositol and cytidine were correlated negatively.
The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism
The metabolic differences between various World Health Organization grades of glioma tumors were analyzed by Chinnaiyan and colleagues 37 via ultrahigh performance liquid chromatography/ tandem mass spectrometry and gas chromatography/mass spectrometry platforms. There was a poor distinction of grade III tumors from either grade II or grade IV owing to overlap in their metabolomic profiles. Amino acid metabolism was altered in grade IV tumors, including increased levels of glutathione and tryptophan and a decrease in Cre levels. An analysis of lipid metabolism in grade IV tumors revealed higher levels of essential and medium chain fatty acids and metabolites associated with carnitine metabolism and lower levels of glycolipids, lysoplipids, and sterols. Although phosphoenolpyruvate and 3-phosphoglycerate levels were increased in grade IV tumors, there was an overall decrease in carbohydrate metabolism. Nucleotide metabolism, particularly pyrimidine catabolism, was found to increase in grade IV tumors. Random forest (RF) analysis was performed to determine which metabolites contributed the most to changes in global metabolism among the different grades of tumors. 2-HG was found to be the most significant biochemical that best delineates tumor grades. An investigation of glycolysis and the oxidative energy metabolism resulted in a more than 7-fold increase in the glycolytic intermediates 3-phosphoglycerate and phosphoenolpyruvate in grade IV tumors compared with grade II tumors. Furthermore, the metabolites 6-P-gluconate, ribose-5-phosphate, serine, and glycine, which contribute to the glycolytic pathway, are significantly increased in grade IV tumors. Interestingly, Gln, which is found to be a major component of tumorigenesis, was not found to be associated with tumor grade.
HYPERPOLARIZED MR IMAGING AND METABOLIC IMAGING IN BRAIN CANCER
MR imaging invaluably benefits many brain diseases patients due to its noninvasive investigation. 13 C MRS has been studied as another diagnostic modality in the brain tumor model of animals and in patients with brain tumor 38 because 13 C labeling compounds provide specific metabolic information with less background noise and can provide dynamic metabolic analysis with 13 C flux analysis. 39 However, the low inherent sensitivity compared with proton MRS must be compensated for in clinical applications. Recently, the novel rapid dissolution process of dynamic nuclear polarization technique was developed to retain strongly polarized nuclear spins in the liquid state. 40 This method can provide more than a 10,000-fold signal enhancement enough to investigate the metabolic changes at the cellular level. Many 13 C labeled compounds are used for detecting the abnormality of metabolic fluxes or the accumulation of metabolites in human cancer 41 such as succinate, 42 a-KG, 43, 44 and pyruvate and ethyl pyruvate. [45] [46] [47] Hyperpolarized 13 C pyruvate and a-KG are now studied actively for brain cancer metabolism and the first clinical trial with hyperpolarized 13 C pyruvate in GBM patients is underway at the University of California, San Francisco (UCSF). This same group at UCSF conducted the first in human clinical study of metabolic imaging in prostate cancer using hyperpolarized 13 C pyruvate. 48
[1-13 C] Pyruvate
A number of preclinical studies in brain tumors have shown that one can distinguish brain tumors from normal tissue by examining in vivo metabolism and assess early response to treatment of high-grade gliomas in animal models. 45, 46 Recently, hyperpolarized 13 C pyruvate kinetic data were acquired from a healthy cynomolgus monkey brain using optimized 13 C coils and pulse sequences which demonstrated the feasibility of using hyperpolarized 13 C pyruvate for assessing in vivo metabolism for brain tumor patients in the near future, 47 like the first human clinical trial using 13 C metabolic imaging for prostate cancer. 48 All these findings suggest that hyperpolarization may be a promising tool for noninvasive cancer diagnosis and treatment assessment in the clinical setting.
[1-13 C] a-Ketoglutarate
Mutations in IDH 1 and 2 present in 70% of lowgrade gliomas and 5-10% of glioblastoma in adults. 10 These mutations are associated with the production of the oncometabolite 2-HG instead of a-KG in the brain tumor, which contributes to the formation and malignant progression of Imaging Brain Metabolism gliomas. 49 This accumulated 2-HG can be detected using in vivo proton MRS acquisitions in patients on a 3T MR imaging scanner and this noninvasive 2-HG detection shows its feasibility as a diagnostic and prognostic biomarker. 50 Also, the injected hyperpolarized 13 C a-KG interrogated the accumulation of hyperpolarized 2HG 43 or the conversion to hyperpolarized 13 C Glu, a potential biomarker for glioma. 44 
Acetate Metabolism in the Brain
Many studies done 10 to 15 years ago show the high use of acetate directly in the brain and its specific use as a glial fuel. [51] [52] [53] Recently, this dependence on acetate as an energy source has been found not only in glial cells but also in GBM and brain metastases. 13 Most studies determine and compare the amount and rate of conversion of isotopically labeled acetate relative to labeled glucose using direct infusion techniques. In one such study, the kinetic parameters for 2-13 C acetate transport and conversion was determined by infusing the compound into rats at different rates. 54 The labeled compound was found to quickly accumulate in the brain, but its conversion to other metabolites is the rate-limiting step. With plasma concentrations around 2 to 3 mmol/L, the rate of acetate use was 0.5 mmol/g per minute and its transport into the brain was calculated to be 0.96 mmol/g per minute. 54 In addition, the 13 C label enrichment of the C4 position of Gln was 44% and the C4 position of Glu was 14% with 2-13 C acetate infusion. 54 Similar studies have been done in humans with plasma concentrations of 1 mmol/L and show similar incorporation of the 13 C label of acetate into Gln and Glu in the brain. [55] [56] [57] The use of acetate in GBM and brain metastases was found using both ex vivo and in vivo NMR techniques after infusions of 1,2-13 C acetate in human orthotopic tumor mouse models. The acetate-to-glucose ratio in five GBM tumor models was around 5-fold higher than in normal control brain tissue. The rate of incorporation of acetate into the citric acid cycle was found to be directly correlated to the amount of acetyl-coenzyme A (CoA) synthetase enzyme 2 (ACSS2). 13 In humans, there are 3 acetyl-CoA synthetase enzymes-ACSS1, ACSS2, and ACSS3. Both ACSS1 and ACSS3 are found in the matrix of the mitochondria; however, ACSS2 is found mainly in the cytosol of the cell. 58, 59 In GBM, the amount of ACSS2 was found to be directly correlated to the grade of the tumor with high staining in (100% positive) in grade IV tumors compared with normal brain tissue. 13 These recent findings have initiated new metabolic research in acetate and cancer progression. 59
Hyperpolarized 1-13 C Acetate
Acetate was one of the first compounds to be hyperpolarized using solid state dynamic nuclear polarization. 60, 61 Since its initial polarization, several improvements in formulation and use of other techniques have significantly improved the percentage of polarization and increased the amount (final concentration) of hyperpolarized acetate that can be generated. [62] [63] [64] The compound has been polarized using both the preclinical dynamic nuclear polarization polarizer and the clinical polarizer. 65 Our laboratory recently reported a method of chemically converting hyperpolarized 1,2-13 C pyruvate to hyperpolarized 1-13 C acetate, 13 C-bicarbonate, and 13 C carbon dioxide using chemical reaction-induced multimolecular polarization. 66 Even with these improvements in 1-13 C acetate polarization, significant progress needs to be made for its rate of conversion to Gln, Glu, acetyl-CoA, and citrate to be useful in diagnostic imaging in the time scale of polarization (<5 minutes). A thorough discussion and execution of using hyperpolarized acetate to diagnosis metabolic changes in diabetic rats was published recently. 65 One of the main mechanisms acetyl-CoA gets shuttled into the mitochondria is through its conversion into acetylcarnitine through carnitineacetyltransferase-1 and then back to carnitine and acetyl-CoA in the mitochondria thorough carnitineacetyltransferase-2. 62 The Stodkilde-Jorgensen group could not detect a difference in the conversion rate of hyperpolarized acetate to acetylcarnitine in the time window of hyperpolarization and stated this is probably owing to low rate of conversion of the enzyme. 65 They observe similar results to the 13 C nonhyperpolarized infusion studies done in the brain; the transport of acetate into specific tissues is fast; however, the rate of conversion is the rate-limiting step and is significantly slower than hyperpolarized 1-13 C pyruvate. Another problem with 1-13 C acetate is that other metabolites that would incorporate the 13 C label such as citrate have similar chemical shifts to acetate. Using in vivo spectroscopy, it is thus difficult to separate the hyperpolarized resonance of hyperpolarized 1-13 C acetate from its metabolite 5-13 C citrate. Other compounds might be better suited to interrogate the citric acid cycle or fatty acid synthesis in the brain in the time scale of polarization. 42, 67, 68 A recent paper by Rolf Gruetter's laboratory illustrates another method of using the hyperpolarization of 1-13 C acetate. 69 His group generated a pulse sequence that transferred the polarized signal in 1,2-13 C acetate from the carbonyl carbon (C1) to the methyl carbon (C2) in the brain of a rat and from the C1 position to a proton on the methyl group of acetate. This method allows for a whole new group of metabolites and chemical resonances to be observed. This transfer sequence could allow for hyperpolarized acetate to become clinical metabolic imaging agent.
Hyperpolarized Metabolic Spectroscopy in Brain Cancer Cell Lines
Hyperpolarized MRS has been applied in brain tumor cell line models in efforts to potentially inform medical decision making in novel and clinically useful ways. Various studies have used this technique, which could provide information on the diagnosis, treatment monitoring, and prognosis of brain tumors in a noninvasive manner.
With regard to diagnosing brain tumors, the differing signal levels provided by hyperpolarized 13 C-labeled pyruvate and 13 C-labeled Lac can be used to distinguish brain tumor and normal brain tissue. In one study, different GBM cell lines (U251 and U87) were used to generate orthotopic xenografts in the rat brain. Levels of 13 C-labeled pyruvate and 13 C-labeled Lac were elevated in the tumor tissue compared with the normal brain tissue. 45 Furthermore, the pattern of histopathology in the cell lines studied correlated with the amount of signal detected. 45 The U251 GBM cell line exhibits large areas of necrosis and hypoxia; in comparison, the U87 GBM cell line has very little necrosis and hypoxia. The signal to noise ratio of hyperpolarized 13 C-labeled Lac, pyruvate, and total carbon was significantly greater in U87 tumors than in U251 tumors; this was thought to be owing to the greater number of viable cells in the U87 line.
Compressed sensing has been used with hyperpolarized MRS to evaluate tumor tissues with heterogeneous metabolic profiles owing to varying levels of necrosis and hypoxia. Compressed sensing allows for the reduction of acquisition time and higher spatial resolution than conventional imaging; this permits the characterization of tumors with a heterogeneous nature like GBM. 46 Differentiation of tumor tissue that was hypoxic/necrotic, nonhypoxic/nonnecrotic, or normal brain tissue in an orthotopic human GBM xenograft model was possible using this technique. Specifically, highly necrotic and hypoxic tumor tissue had absent or low levels of 13 C-labeled pyruvate and 13 C-labeled Lac, whereas tumor tissue with minimal levels of necrosis and hypoxia had high levels of 13 C-labeled pyruvate and 13 C-labeled Lac. 46 If used in the clinic, hyperpolarized pyruvate with MRS and compressed sensing could be particularly useful in noninvasively determining tumor tissue types in GBM.
In addition to characteristic signal levels of hyperpolarized 13 C-labeled metabolites in tumor versus normal brain tissue, the apparent rate constant (k PL ) for the conversion of pyruvate to Lac can also be used to distinguish cancer and normal tissue. Orthotopic xenografts of C6 glioma had larger Lac/pyruvate ratios as well as a larger k PL compared with normal tissue. 70 Furthermore, k PL may even be a more robust marker than the Lac/ pyruvate ratio in distinguishing cancerous brain tissue. The k PL has significantly less variability than the Lac/pyruvate ratio when used to differentiate tumor tissue from normal brain tissue. 70 Hyperpolarized techniques could also be applied to monitor treatment response in brain tumors; tumor response to RT and to different methods of chemotherapy, such as temozolomide (TMZ), everolimus, and LY294002, have been studied with hyperpolarized 13 C-labeled metabolites as a metric for response. TMZ is an alkylating agent used to treat brain tumors and is the first-line agent in treating GBM. Everolimus and LY294002 are drugs that target the PI3K/AKT/mammalian target of rapamycin pathway, which regulates the cell cycle. Using conversion of hyperpolarized pyruvate to Lac as a metric, tumor response to radiation treatment by a C6 glioma orthotopic tumor model was examined. By 72 hours after irradiation, the ratio of hyperpolarized Lac in tumor-to-maximum pyruvate in blood vessels was decreased by 34% compared with untreated tumors. 71 Treatment with TMZ was found to decrease the hyperpolarized pyruvate/Lac ratio in an orthotopic rat model of human GBM. 72 This response could be detected just 1 day after TMZ treatment, whereas imaging-based evidence of tumor volume shrinkage owing to treatment did not occur until 5 to 7 days after treatment. 72 These results were supported by a second study that used a bioreactor to maintain GBM cells treated with TMZ during hyperpolarized imaging. TMZ-treated cells showed a decrease in conversion of hyperpolarized pyruvate to Lac compared with untreated cells. 73 Additionally, the authors of the study found that treatment with TMZ correlated with a decrease in pyruvate kinase, which is a glycolytic enzyme that indirectly controls pyruvate to Lac conversion. 73 In hyperpolarized studies of everolimus treatment in an orthotopic rate model of GBM, a significant drop in hyperpolarized Lac/pyruvate ratio compared with control was observed 7 days after treatment. 74 At this same time point, conventional MR imaging was unable to detect a difference in tumor size between the treated and control group. It was not until 15 days after treatment that inhibition of tumor growth was appreciated on MR imaging. 74 Bioreactor studies of everolimus and LY294002 treated GBM cells support these results. Decreased hyperpolarized Lac levels were observed in cells treated with these drugs compared with untreated controls. 75, 76 In addition to decreased hyperpolarized Lac levels, decreased phosphocholine levels were found to correlate with treatment using these agents. 75 This is expected because the PI3K/AKT/mammalian target of rapamycin pathway controls both the synthesis of phosphocholine and Lac via a common transcription factor hypoxia inducible factor-1-a. 75 The balance between glycolysis and oxidative phosphorylation can provide important information regarding treatment response. Because many cancer cells derive most of their energy via glycolysis and normal cells via oxidative phosphorylation, the ability to detect if a tumor mainly uses one pathway over the other can indicate continued malignancy or positive response to treatment. One study was able to detect and quantify conversion of hyperpolarized 13 C-bicarbonate from 13 C-pyruvate in vivo for the first time. 77 Because CO 2 is a byproduct of the flux from pyruvate to acetyl-CoA, bicarbonate can be used as a surrogate marker for mitochondrial metabolism, which is predominant in normal cells. The study found that Lac levels were significantly greater in glioma, and bicarbonate levels were significantly greater in normal brain tissue. 77 A bioreactor study of GBM cells with mutated IDH1 showed elevated levels of hyperpolarized 2-HG compared with GBM cells with wild-type IDH1. 75 IDH mutation was also found to correlate with decreased activity of branched chain amino acid transaminase. 44 Branched chain amino acid transaminase catalyzes the transamination of branched chain amino acids while converting a-KG to Glu. Thus, in cells with IDH1 mutation, a decrease in branched chain amino acid transaminase activity is expected to correlate with decreased Glu production. This was found to be the case in a bioreactor study of GBM cells with IDH1 mutation; hyperpolarized 13 C-Glu production was decreased in mutant cells compared with wild-type cells. 44 As biomarkers of metabolic imaging, hyperpolarized 2-HG and Glu may potentially provide useful information in regards to detecting IDH1 mutation and treatment monitoring of brain tumors with IDH1 mutation.
Currently, the main tool for cancer diagnosis and monitoring is 18 fluoro-2-deoxyglucose (FDG)-PET. In brain tumors, however, FDG-PET shows increased signal in surrounding brain tissue owing to the high uptake that masks the signal generated by the tumor itself. 71 Furthermore, pseudoprogression is a misleading phenomenon in which there is contrast enhancement of the tumor after treatment with radiotherapy or chemotherapy despite positive tumor response to the treatment. Diagnosis and treatment monitoring with hyperpolarized metabolic techniques could help mitigate this confounding clinical problem.
IMAGING INFLAMMATION IN THE BRAIN
Broadly, it is known that the heterogeneous microenvironment of brain tumors includes both the tumor and a variety of altered stromal components. These altered stromal components include a variety of cells such as the vascular epithelium and various infiltrative inflammatory cells. The genesis of the milieu has not yet been determined, but it is clear that the net effect of the local environment is mostly tumor supportive. Indeed, cells present at these sites do not behave as they would in their normal microenvironment. For example, tumorassociated macrophages and neutrophils exhibit a graded expression and functional pattern that is consistent with a tumor supportive role. When this tumor-supportive function is blocked, then glioma growth and progression is delayed. [78] [79] [80] In the case of the adaptive immune system there can be an abundance of regulatory T (Treg) cells 81, 82 within the glioma that are immune suppressive and participate in blocking immune recognition and clearance of the glioma. Most recently, the immune checkpoints have been shown to be operational in a subset of glioma patients 83, 84 and various inhibitors have shown promising results in preclinical models of glioma. 85, 86 Such responses would have been unthinkable a decade ago. Currently, there are clinical trials underway at a host of institutions to study these immune checkpoint blockade inhibitors in the context of GBM and neuroblastomas.
There is a deep need to understand how and when the immune system begins to interact with the tumor environment and to understand how the status of the various types and states of the inflammatory cells might predict response to various classes of immune checkpoint inhibitors. There are starting points to dissect out these contributions, but each of the currently existing approaches has limitations. Broadly, people often interpret the flair phenomenon as inflammation, but this observation can also occur owing to increased vascular permeability in and around tumor sites. Indeed, when patients are treated with modern chemotherapy protocols, 20% to 30% of patients yield pseudoprogression, an increase in T2 bright areas owing to "inflammatory" processes. Effectively categorizing new tumor growth versus inflammation is critically important for managing patient care. 87 Similarly, phase-weighted MR imaging can also be used to find inflammatory lesions, but this again has been attributed primarily to an increase in the leaky blood vessels and an increase in accumulation of heme from hemoglobin at the site of inflammation. Similar to 111 indium oxine labeling of white blood cells for studying inflammation by SPECT imaging, macrophages have been loaded ex vivo with superparamagentic iron oxide nanoparticles and then their migration to otherwise T2 bright regions can be followed. Because these are T2* agents the tumor and surrounding brain tissue must be T2 bright a priori. The normal brain is well-suited for such an application, but as mentioned, an increase in vascular permeability can result in locally high concentrations of heme that also result in T2 darkening. In the context of spinal injury and traumatic brain injury, diffusion tensor imaging can be useful for detecting demyelination that is downstream of neuroinflammation. 88, 89 However, particularly in the case of heterogeneous GBM assigning changes in diffusion to a specific cell type or biochemical pathway will be challenging. Classic targeting of surface receptors using contrast agents has been limited by the sensitivity of MR imaging relative to the abundance of surface receptors present on the cells and the requirement for breakdown of the blood-brain barrier. 90 Enzymatic amplification of the targeting signal might solve this problem. In preclinical models of inflammation, bis HT-DTPA-gadolinium uses a polymerization strategy for determining myeloperoxidase enzymatic activity in vivo. 91 This has shown to be selective in the context of myeloperoxidase À/À mice. 92 However, this requires induction of free radical polymerization processes in vivo, this technique has not been adopted widely. Others have used MRS for studying changes in NAA, choline, and Cre levels, which correlate with changes in the neural tissue. However, it is not clear whether the subsequent increase NAA has been proven to be cell type specific through either cell depletion studies or knockout mice. 93 As such, there remains significant need for pathway, cell-type-specific molecular probes, or metabolic profiling for studying inflammation in the context of tumor initiation, growth, and treatment in vivo. Indeed, the need for enzymatic amplification and improvement in signal to noise ratio suggests that hyperpolarized MR imaging may be able to address several of the current limitations for imaging inflammation in the context of tumors in near future.
CHEMICAL EXCHANGE SATURATION TRANSFER IMAGING IN BRAIN CANCER
Chemical exchange saturation transfer (CEST) imaging offers enhanced indirect detection of exchangeable protons species, which can be endogenous such as hydroxyl, amide, and amine protons in peptides or exogenously introduced such as liposomes. There are several classification schemes of CEST techniques that are currently in use: (1) classification based on exchange type-protons, molecules, or compartments; (2) diamagnetic CEST or paramagnetic CEST (paraCEST). 94 The CEST mechanism relies on the selective RF saturation of exchangeable proton species that resonate at a different frequency relative to the bulk water (w4.75 ppm). The bulk water signal becomes attenuated to some extent after solute protons (micromolar to millimolar range) exchange with that of the bulk (w110 mol/L). Provided that the RF saturation is long enough (seconds range) and the solute exchange rates are sufficiently fast (millisecond residence time), significant saturation will eventually be visible on the bulk water signal (S sat ). Normalizing the original proton spectrum without saturation (S 0 ) with S sat (S sat /S 0 ) leads to the CEST spectrum or Z-spectrum. The inverted peaks in the Z-spectrum then correspond with the selectively saturated proton species and the bulk water peak is redefined to 0 ppm by convention. The asymmetric magnetization transfer ratio plot is subsequently obtained by subtracting the left half of the Z-spectrum (>0 ppm) from the right half to remove the bulk water signal for better visual representation. 94 For the diamagnetic CEST effect, the saturation frequency ranges from 0 to 7 ppm, whereas for paraCEST agents, the offset frequency range can be greater than 100 ppm, which offers a much cleaner saturation excitation profile.
The CEST signal is a function of CEST agent concentration, pH, temperature, magnetic parameters (relaxation rate, magnetic field strength), and imaging parameters (repetition time, RF irradiation amplitude, and power, as well as imaging sequence). For the CEST effect to be observed efficiently, a relatively slow to intermediate exchange rate on the MR time scale is required. If the exchange rate is too slow, the saturated protons could have relaxed back to equilibrium by the time it affects to the bulk water pool; if the exchange rate is too fast, not enough saturation on the solute proton pool will have been accumulated. The CEST effect also scales with B 0 owing to better spectrum separation, so more accurate selective saturation and a higher B 0 leads to longer T 1 water , resulting in longer storage of saturation in the bulk water pool. However, the specific absorption rate increases quadratically with B 0 , which places a constraint on sequence design and applications. Please refer to 94, 95 for a comprehensive review of optimization and quantification techniques involved in CEST imaging. Herein, we focus on the potential applications of CEST to image brain cancer.
Glutamate Chemical Exchange Saturation Transfer
Glutamate is a major excitatory neurotransmitter in the brain that is restricted to the synaptic and perisynaptic space of glutamatergic synapses under normal physiologic conditions. Glu released by malignant gliomas has been shown to induce seizure and promote excitotoxicity, which help the invasion of tumor cells into normal tissues 96, 97 CEST imaging of Glu (GluCEST) can provide noninvasive monitoring of Glu level in vivo, which can potentially be used to monitor disease progression and assess treatment efficacy.
GluCEST relies on the exchange of protons in the amine group with the bulk water. The resonance frequency of the amine protons is pH dependent and centered around 3 ppm relative to the bulk water resonance frequency. 98 In phantom studies at 7T and at a pH of 7, it has been demonstrated that under physiologic concentrations, the majority of the CEST effect with saturation at 3 ppm (Z-spectrum scale) came from Glu (w70%-75% of total CEST contrast), whereas other metabolites contribute relatively little (GABA w12%, <6% from Cre, and minimal from other metabolites). In vivo experiment with middle cerebral artery occlusion-induced stroke models showed much higher GluCEST contrast compared with the normal contralateral side. GluCEST imaging offers a resolution of 0.27 Â 0.27 Â 2 mm for animal model and 1.9Â 1.9 Â 2 mm for human subjects with an imaging time of around 16 seconds per slice (1 average), which is much better compared with conventional chemical shift imaging techniques in terms of spatial and temporal resolution. The total scan time is around 12 minutes, including the acquisition of B0 and B1 maps needed for corrections. 98, 99 
Glucose Chemical Exchange Saturation Transfer
Tumors tend to exhibit high glucose uptake, which forms the basis of FDG-PET. Noninvasive CEST imaging of unlabeled glucose (GlucoCEST) offers an alternative to assess glucose uptake in vivo without the use of ionizing radiation. 100 GlucoC-EST rests on selective saturation of the hydroxyl protons of glucose at 1.2, 2.1, and 2.9 ppm. In two colorectal cancer models (LS174T and SW1222), GlucoCEST images taken 60 minutes after glucose infusion (1.1 mmol/kg, intraperitoneally) shows significant correlation with FDG-PET images (r 2 5 0.70; P<.01), offering a possible nonradioactive alternative and better spatial resolution (1 Â 1 Â 3 mm) to probe intratumoral heterogeneity that can readily be translated to GBM and other cancer systems.
Creatine Chemical Exchange Saturation Transfer
Creatine kinase reaction plays a vital role in energetics by regulating adenosine triphosphate reservoir (Cr 1 adenosine triphosphate 1 adenosine triphosphate 1 phosphocreatine 1 H 1 ). Reduced total Cre concentration has been shown to be a predictor for gliomas progression. [101] [102] [103] With traditional MRS techniques, it is possible to detect the total Cre (Cr 1 phosphocreatine), but not the individual components. CrEST imaging provides a way to assess the free Cre level in vivo with much improved spatial and temporal resolution. 104 However, quantification using only asymmetry analysis would be problematic owing to contributions from semisolid magnetization transfer and aliphatic nuclear Overhauser effect. So, the entire Z-spectrums for each pixel must be acquired for Lorentzian spectral fitting (5 components: free water, bound water, CrEST w2 ppm, magnetization transfer, and CEST), which could lead to greatly increased scan time (w30 minutes for the brain). After fitting, the integral of Cre component in the brain tumor region was shown to decrease with disease progression in an intracranial cancer model, consistent with previous studies. And interestingly, the tumor margin as defined by the Cre map is sometimes larger than those obtained from traditional MR imaging contrast, such as proton density image, which may indicate that tumor could have negative impacts on the energetics of surrounding tissues. 105 
Amide Proton Transfer
CEST imaging of amide protons is based on saturation at 3.5 ppm from the water peak. Termed amide proton transfer, it is assumed to originate from the exchangeable amide protons of mobile tissue proteins and peptides. In tumors, amide proton transfer contrast increases as the tumor progresses, presumably owing to increased cellular amide proton content compared with normal tissues, whereas intracellular pH stays relatively constant. 94, [105] [106] [107] [108] In ischemic models, however, the amide proton transfer contrast is lower compared with the normal tissues, which could be attributed to lower amide proton exchange rate resulting from decreased intracellular pH. 109, 110 Paramagnetic Chemical Exchange Saturation Transfer
ParaCEST agents are mainly metal ion complexes, which offers protons exchanging slow enough for detection (eg, lanthanide groups, iron, and nickel). Aside from having a large chemical shift away from the bulk water pool, paraCEST agents can be designed to target specific biological processes and improve detection sensitivity by polymerization to increase the number of exchange sites per mole. They have been used to measure tissue pH, temperature, and enzymatic activity, as well as specific metabolite levels. But because paraCEST agents are administered exogenously, tissue perfusion and clearance tend to complicate the quantification of CEST contrast. One example of paraCEST agent for in vivo glioma detection is based on dendrimer labeled with Europium CEST agents and fluorescent labels for dual modality imaging ([DyLight 680]-Eu-G5PAMAM). 111 Ali and colleagues 111 have shown the paraCEST agent could be detected in the tumor region after around 10 minutes, primarily due to an impaired bloodbrain barrier in the glioma models.
Superparamagnetic Iron Oxide Nanoparticles
Superparamagnetic iron oxide nanoparticles (SPION) act as T2-shortening agents, providing negative contrasts in MR imaging. They are available commercially and have been used extensively for cell labeling after modifications. 112, 113 Recently, SPION has been conjugated with recombinant human epidermal growth factor for the in vivo detection of brain malignancies in C6 glioma models that overexpress epidermal growth factor receptor. 114 After 24 hours after intravenous injection (0.3 mg/kg), SPION-epidermal growth factor showed much better accumulation inside the tumor region compared with bare SPIONs; reflected laser scanning revealed internalization of SPIONepidermal growth factor inside the glioma cell cytoplasm. 114 It has also been shown that radiation sensitizes the glioma model for better uptake of SPIONs conjugated with antibodies targeting membrane heat shock protein 70. 115 These early preclinical studies were promising applications of SPIONs, but toxicity issues need to be further addressed before in vivo applications in human.
HYPERPOLARIZED XENON IMAGING IN THE BRAIN
Hyperpolarized xenon-129 (Xe) 116 has been developed for biomedical MR imaging over the last 25 years, with most emphasis on void-space and pulmonary imaging. 117, 118 Because inhaled (or injected) xenon travels readily to the brain (and acts as an anesthetic), 119 it may also function as a novel contrast agent for brain imaging. Indeed, nonpolarized xenon gas has been used for enhancing computed tomography scans of the brain for decades. 120 In recent years, limited MR imaging studies have already successfully shown hyperpolarized 129 Xe gas dissolved in the brain tissue. Below is a brief overview of the current state of clinical and preclinical work applying hyperpolarized 129 Xe to brain MRS/MR imaging. 129 Xe has many physical and magnetic properties that make it well-suited for physiologic imaging. This inert gas (spin 5 1/2) is nonradioactive, has no biological background signal, and dissolves readily into blood, tissue, and fat. 121 In fact, xenon's differential solubility (owing to a slight hydrophobicity) may be developed as a form of contrast to distinguish areas of the brain that are rich in water versus lipids. 116 Importantly, 129 Xe possesses an incredibly sensitive chemical shift range (d > 7500 ppm), which makes it well-suited to function as a spectroscopic chemical sensor. 122 Indeed, differences in chemical shift have been shown to distinguish 129 Xe inside cryptophane cages that are linked to different biological targets. 123 Furthermore, 129 Xe MR spectra are exceedingly simple to analyze, and typically only consist of a handful of sharp, well-resolved NMR peaks that correspond to different chemical and magnetic environments. The relaxation rate (T 1 ) of 129 Xe can also be used to differentiate contact with different tissue types, 124 as well as oxygenated versus deoxygenated blood. 125 Because of its relatively low gyromagnetic ratio (g Xe /g H w -0.28) and natural abundance (w26%) compared with 1 H, the signal from 129 Xe at thermal equilibrium is insufficient for conventional MR imaging detection. 129 Xe gas can be hyperpolarized through spin-exchange optical pumping 126 -a two-step process where angular momentum from resonant, circularly polarized laser light is transferred to the electronic spins of an alkali metal vapor, then subsequently exchanged with the 129 Xe nuclei via gas phase collisions. This results in a buildup of 129 Xe nuclear spin polarization, which creates MR signal enhancement values of 4 to 5 orders of magnitude compared with thermal equilibrium-allowing 129 Xe MRS/MR imaging for biomedical studies. This enhanced signal decays Imaging Brain Metabolism over a time constant (T 1 ) that depends on the immediate environment of the gas, and can range from a few seconds to several hours. Spinexchange optical pumping takes place in a dedicated 'hyperpolarizer' 127 that dispenses the polarized gas into a Tedlar bag for administration to the patient; owing to recent improvements in technology and methodology, 129 Xe nuclear spin polarization values of greater than 90% have been reported. 128 Hyperpolarized 129 Xe can be administered to patients through either inhalation or intravenous injection, and it has been shown that both methods lead to comparable 129 Xe concentrations in the brain. 129 Owing to the decreased invasiveness of the procedure, gas inhalation is typically the method used for in vivo studies. In this case, the patient will inhale as much of the gas as possible (about 0.5 L) along with atmospheric air or O 2 , followed by a breath hold (15-60 seconds). The xenon travels from the lungs to the brain relatively quickly (approximately 5 seconds). 130 For preclinical studies, the animal is usually intubated and an MR-compatible respirator controls the administration of the gas. For intravenous injections, the hyperpolarized 129 Xe is typically dissolved in saline or an emulsion (such as perflurbon or Intralipid) before injection. As with all hyperpolarized contrast agents, a major constraint is that the nonrenewable enhanced signal decays with time. When held in pristine laboratory conditions, hyperpolarized 129 Xe lasts for hours. 131 However, when administered in vivo, the enhanced signal is depleted over the course of about 1 minute owing to interactions with its environment. Indeed, the hyperpolarized T 1 of 129 Xe in the blood is only about 5 seconds, owing to the abundance of paramagnetic hemoglobin. 125 Additionally, the very act of acquiring a signal further depletes the magnetization of the contrast agent in a nonrenewable fashion. To combat this, many MR acquisitions take advantage of a 'fast low-angle shot' sequence to mitigate signal losses caused by RF pulsing. The silver lining to this time constraint is that the effective clearance rate of the 129 Xe MR signal can be quite fast to allow for multiple studies in a single patient session.
Since the initial demonstration of hyperpolarized 129 Xe MR imaging in a rat brain 132 and 129 Xe MRS in a human brain 130 in 1997, the field has grown steadily. 129 Xe brain MRS typically displays a handful of discernable peaks that can be attributed to 129 Xe in the gas phase, dissolved in blood, and dissolved in different brain tissues (ie, gray and white matter). 124, 133 It has been shown that xenon has an increased proclivity for gray matter compared with white matter (with different T 1 rates), and perfusion between brain compartments can also be tracked. 124 A range of different administration methods, including inhalation and intravenous injection, have been compared and numerically modeled to show that inhalation is the preferred method of supplying the brain with hyperpolarized 129 Xe gas. 124 A differential distribution of 129 Xe signal in the cerebral cortex in rats was found after a pain stimulus (and corroborated with 1 H MR imaging), which is early work in the development of 129 Xe for functional MR imaging. 134 Indeed, 129 Xe may be developed further for functional MR imaging through an increase in concentration (owing to increased blood flow to regions of brain activity) and longer 129 Xe T 1 values in oxygenated blood (vs deoxygenated blood) 116 -acting as a proxy for blood oxygen level-dependent contrast imaging. It has also been shown that a perfusion deficit, such as one caused by a stroke, can be detected with changes in 129 Xe signal. Because 129 Xe is a safe, inert, and inhalable contrast agent, it may prove to be a safer MR contrast agent compared with injectable gadolinium-based tracers. 134 Moving forward, several advances in hyperpolarized 129 Xe brain MRS/MR imaging are on the horizon. Most predominantly will be targeted imaging using functionalized biomarkers in the form of a cryptophane complex. As 129 Xe diffuses through the cage-shaped molecule, its chemical shift is changed-which allows it to be used as a sensitive chemical sensor that can differentiate whether the cage molecule is attached to a biomarker. 123 However, because the amount of 129 Xe associated with these targeted cryptophane cages at a given time is small, the resulting signal is often quite weak. One way around this is through a technique called hyperpolarized CEST, which saturates the " 129 Xe in cryptophane" resonance while monitoring the increased depletion of the " 129 Xe gas resonance" as the xenon transfers between the targeted cage complex and the spin reservoir. 135 This method can be used to indirectly detect the presence of low concentrations of transferrable species that are spectroscopically discernable, and has been recently demonstrated to show targeting of the human brain microvascular endothelial cells that comprise the bloodbrain barrier. 136 Another potential improvement to detection sensitivity would be through the implementation of a remote detection protocol, where the step of RF encoding of nuclear spins is physically separated from the signal detection. This can be used to improve sensitivity through optimizing the detection filling factor; under this scenario, 129 Xe in the entire brain would be encoded at once, but then detected using a small surface coil placed over the jugular vein to monitor the 129 Xe as it exits the brain. 137 Hyperpolarized xenon imaging applications in the brain are still at a nascent stage but this is a promising area that may provide some innovative applications to interrogate brain functions in realtime.
SUMMARY
This article reviews the existing and emerging techniques of interrogating metabolism in brain cancer from well-established proton MRS to the promising hyperpolarized metabolic imaging, GlucoCEST, hyperpolarized CEST, and imaging inflammation. Many of these techniques are at an early stage of development and clinical trials using these techniques are in progress in brain cancer patients to establish the clinical efficacy of these techniques. Nonetheless, it is likely that in vivo metabolomics and metabolic imaging is the next frontier in brain cancer diagnosis and assessing therapeutic efficacy; with the combined knowledge of genomics and proteomics a complete understanding of tumorigenesis in brain might be achieved.
